Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05041426 · ClinicalTrials.gov registry record · Phase 2
Letermovir for CMV Prevention After Lung Transplantation
A Phase 2 study, sponsored by Fernanda P Silveira, MD, MS.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT05041426: Completed Phase 2 study, sponsored by Fernanda P Silveira, MD, MS.
NCT05041426 is a Phase 2 study that has completed, run by Fernanda P Silveira, MD, MS. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05041426, a Phase 2 study, has completed, sponsored by Fernanda P Silveira, MD, MS.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is an interventional, open-label, single center, pilot study with historical controls to test the efficacy of letermovir (LET) for the prevention of CMV infection and disease in adult lung transplant recipients (LTRs) with idiopathic pulmonary fibrosis (IPF).
Primary Outcome
Number of lung transplant recipients with idiopathic pulmonary fibrosis with CMV infection or disease during letermovir prophylaxis.
Interventions
- DRUG Letermovir
- DRUG Valganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-12-06 |
| Est. Completion | 2025-03-03 |
| Phase | Phase 2 |
What the finished NCT05041426 record still lists
NCT05041426 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Letermovir is the first listed.
NCT05041426 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05041426 about?
NCT05041426 is a clinical study titled "Letermovir for CMV Prevention After Lung Transplantation". This is an interventional, open-label, single center, pilot study with historical controls to test the efficacy of letermovir (LET) for the prevention of CMV infection and disease in adult lung transplant recipients (LTRs) with idiopathic pulmonary fibrosis (IPF).
What is the current status of trial NCT05041426?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-12-06. Estimated completion is 2025-03-03.
What interventions are being tested in trial NCT05041426?
The interventions under investigation include: Letermovir (DRUG), Valganciclovir (DRUG).
Who is sponsoring clinical trial NCT05041426?
This trial is sponsored by Fernanda P Silveira, MD, MS, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05041426's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI